Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Osteoporos Int ; 33(1): 273-282, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34402949

RESUMO

This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. INTRODUCTION: Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. METHODS: Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. RESULTS: A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. CONCLUSION: Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.


Assuntos
COVID-19 , Osteoporose , Preparações Farmacêuticas , Estudos de Coortes , Feminino , Humanos , Osteoporose/tratamento farmacológico , Osteoporose/epidemiologia , Estudos Retrospectivos , SARS-CoV-2
2.
Artigo em Inglês | MEDLINE | ID: mdl-36155103

RESUMO

OBJECTIVE: Papillary thyroid cancer (PTC) has many variants and most of them are mild tumors. Oncocytic variant (OV) is a rare subtype of PTC. There are controversial results about its prognosis in the literature. We investigated its aggressivity and clinical course by comparing it with classical variant (CV) and tall cell variant (TV) of PTC over a stage-matched design. MATERIAL AND METHODS: Pure 100 OV, 71TV and 1219 CV were included in this retrospective cohort study. OV was compared with CV and TV according to independent prognostic parameters. OV was also compared stage by stage with CV and TV for recurrence. RESULTS: Mean age was 46,8 years and male/female ratio 25/75 for OV. The recurrence rates in our study were 16% in OV, 13,5% in CV and 56% in TV. There is a statistically significant difference according to recurrence between stage I and stage IV OV and CV (p=0.023, p=0.03, respectively). There is also a statistically significant difference between stage I and stage IV OV and TV according to recurrence (p=0.001, p=0.024, respectively). OV can be supposed to behave between CV and TV, but very closer to CV. CONCLUSIONS: OV seems to be slightly more aggressive than CV. Despite an inadequate sample size for stage II and III, our findings imply an increased recurrence risk for OV than CV at the advanced stages (stage III and IV) and CV has an unfavorable prognosis than OV at early stages (stage I and II) according to stage-matched model.


Assuntos
Carcinoma Papilar , Neoplasias da Glândula Tireoide , Humanos , Masculino , Feminino , Câncer Papilífero da Tireoide/patologia , Neoplasias da Glândula Tireoide/patologia , Estudos Retrospectivos , Prognóstico
3.
Zentralbl Neurochir ; 64(4): 178-81, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14634883

RESUMO

A case of isolated brucella disk infection mimicking fragmented disk herniation is presented. MRI studies were performed two times in 6 months, both of which did not show any signs of spondylitis. Since brucella infections are seen along with spondylitis, this case has attracted our attention. We focused on radiological findings in this pure brucella disk infection.


Assuntos
Brucelose/patologia , Discite/patologia , Deslocamento do Disco Intervertebral/patologia , Adulto , Antibacterianos/uso terapêutico , Brucelose/tratamento farmacológico , Diagnóstico Diferencial , Discite/diagnóstico , Discite/tratamento farmacológico , Doxiciclina/uso terapêutico , Humanos , Deslocamento do Disco Intervertebral/diagnóstico , Imageamento por Ressonância Magnética , Masculino , Espondilite/patologia , Estreptomicina/uso terapêutico
4.
Zentralbl Neurochir ; 65(2): 84-7, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15118923

RESUMO

Vertebral Eosinophilic Granuloma (EG) is a frequently reported disease, but further dissemination rarely occurs when the initial lesion is in the lumbar region. We present a case of EG, initially located in L5 vertebra, which disseminated to the skeletal bones and pulmonary system months after total excision in an adult.


Assuntos
Granuloma Eosinófilo/cirurgia , Complicações Pós-Operatórias/patologia , Neoplasias da Coluna Vertebral/cirurgia , Adulto , Granuloma Eosinófilo/diagnóstico , Feminino , Humanos , Imageamento por Ressonância Magnética , Complicações Pós-Operatórias/diagnóstico por imagem , Radiografia , Reoperação , Neoplasias da Coluna Vertebral/diagnóstico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA